# Genexine

> Genexine is a VC fund in Seongnam backing Biotechnology and Health Care. See 2 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seongnam, South Korea
- Total investments: 2
- Last investment: Feb 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/genexine-inc-
- Website: http://www.genexine.com/

Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives.

## Contacts

5 contacts available for Genexine. Shizune tracks 1 team members at Genexine. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/genexine?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Neil K. Warma | President and CEO | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Y-Biologics | Y-Biologics is specialized in antibody drug since its inception has focused on research and development. They have successfully constructed the unique human antibody library Y-max ABL and new dual antibody platform technology ALiCE. Based on this, they have developed various antibody drugs and become a leading company in the globalimmuno-chemotherapeutic drug market They are doing their best to leap forward. | $24.9M | Venture - Series Unknown | Feb 24, 2022 |  |
| GI Innovation | GI Innovation is a South Korean bio-venture company, integrating basic science and translational innovation in developing biologics for patients around the world. GI Innovation’s strategic focus is on immuno-oncology and inflammation/immunology diseases. GI Innovation has established GI-SMART platform technology that is designed to acceleratethe development of biologics through the efficient optimization of multi-targeting fusion protein therapeutics with high quality and high productivity. | $53.1M | Series B | Apr 12, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [HK inno.N](https://shizune.co/investors/profile/cj-healthcare-corp) — VC Fund, 1 deal together
- [Dayli Partners](https://shizune.co/investors/profile/dayli-partners) — VC Fund, 1 deal together
- [DS Asset Management](https://shizune.co/investors/profile/ds-asset-management) — VC Fund, 1 deal together
- iMarket Korea — VC Fund, 1 deal together
- [Kolon Investment](https://shizune.co/investors/profile/kolon-investment) — VC Fund, 1 deal together
- [Korea Omega Investment](https://shizune.co/investors/profile/korea-omega-investment) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Genexine invest in?

Genexine invests primarily in Biotechnology and Health Care startups, most often at Series B and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Genexine?

Public channels for Genexine include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Genexine?

The team at Genexine includes Neil K. Warma (President and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co